Total Payments
$7,343
2023 Payments
$136.31
Companies
43
Transactions
488
Medicare Patients
1,956
Medicare Billing
$237,359
Payment Breakdown by Category
Food & Beverage$7,273 (99.0%)
Gifts$53.32 (0.7%)
Education$16.52 (0.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,273 | 485 | 99.0% |
| Gift | $53.32 | 1 | 0.7% |
| Education | $16.52 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AbbVie Inc. | $1,478 | 92 | $0 (2023) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $1,280 | 100 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $624.05 | 42 | $0 (2022) |
| Janssen Biotech, Inc. | $477.81 | 29 | $0 (2022) |
| Gilead Sciences, Inc. | $451.52 | 35 | $0 (2022) |
| Allergan, Inc. | $282.07 | 25 | $0 (2020) |
| Celgene Corporation | $208.39 | 12 | $0 (2022) |
| GlaxoSmithKline, LLC. | $201.05 | 13 | $0 (2019) |
| INTERCEPT PHARMACEUTICALS, INC. | $178.06 | 11 | $0 (2022) |
| Ironwood Pharmaceuticals, Inc | $177.00 | 12 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $136.31 | 3 | AbbVie Inc. ($104.14) |
| 2022 | $1,748 | 108 | ABBVIE INC. ($456.20) |
| 2021 | $1,442 | 89 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($450.07) |
| 2020 | $663.27 | 43 | AbbVie Inc. ($190.00) |
| 2019 | $1,080 | 73 | Takeda Pharmaceuticals U.S.A., Inc. ($197.63) |
| 2018 | $960.03 | 68 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($181.68) |
| 2017 | $1,314 | 104 | Allergan Inc. ($194.30) |
All Payment Transactions
488 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/02/2023 | AbbVie Inc. | — | Food and Beverage | In-kind items and services | $104.14 | General |
| 04/19/2023 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $17.94 | General |
| Category: Genetic Disease | ||||||
| 02/22/2023 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: Gastroenterology | ||||||
| 12/20/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.92 | General |
| Category: Gastroenterology | ||||||
| 12/15/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $28.15 | General |
| Category: Neuroscience | ||||||
| 12/14/2022 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $16.83 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/08/2022 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: Immunology | ||||||
| 12/01/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.17 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/17/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Immunology | ||||||
| 11/17/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $17.08 | General |
| Category: Immunology | ||||||
| 11/17/2022 | Takeda Pharmaceuticals U.S.A., Inc. | ENTYVIO (Biological) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: INTERNAL MEDICINE | ||||||
| 11/10/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.48 | General |
| Category: Neuroscience | ||||||
| 11/09/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Gastroenterology | ||||||
| 11/09/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $7.10 | General |
| Category: Immunology | ||||||
| 11/08/2022 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $12.61 | General |
| 11/03/2022 | Janssen Biotech, Inc. | STELARA (Biological) | Food and Beverage | In-kind items and services | $31.86 | General |
| Category: Immunology | ||||||
| 11/03/2022 | Ironwood Pharmaceuticals, Inc | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $19.40 | General |
| Category: GI | ||||||
| 11/02/2022 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $10.72 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/26/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.58 | General |
| Category: Neuroscience | ||||||
| 10/13/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $9.96 | General |
| Category: IMMUNOLOGY | ||||||
| 10/12/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.50 | General |
| Category: Gastroenterology | ||||||
| 10/12/2022 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $21.20 | General |
| Category: Gastroenterology | ||||||
| 10/11/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $21.79 | General |
| Category: Neuroscience | ||||||
| 10/11/2022 | ABBVIE INC. | VIBERZI (Drug), LINZESS | Food and Beverage | In-kind items and services | $18.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/06/2022 | Janssen Biotech, Inc. | REMICADE (Biological), SIMPONI, SIMPONI ARIA | Food and Beverage | In-kind items and services | $23.94 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 12 | 649 | 719 | $347,065 | $80,358 |
| 2021 | 12 | 696 | 749 | $385,195 | $88,771 |
| 2020 | 12 | 611 | 694 | $237,880 | $68,230 |
Total Patients
1,956
Total Services
2,162
Medicare Billing
$237,359
Procedure Codes
36
All Medicare Procedures & Services
36 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 146 | 199 | $36,815 | $14,630 | 39.7% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 70 | 72 | $54,000 | $13,889 | 25.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 64 | 64 | $65,600 | $13,784 | 21.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 84 | 97 | $26,190 | $8,858 | 33.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 81 | 81 | $70,875 | $8,355 | 11.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 44 | 44 | $18,040 | $5,013 | 27.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 22 | 22 | $16,500 | $4,370 | 26.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 41 | 41 | $26,445 | $3,431 | 13.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 40 | 40 | $10,800 | $3,222 | 29.8% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 19 | 19 | $10,070 | $1,952 | 19.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 11 | 11 | $8,250 | $1,701 | 20.6% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 27 | 29 | $3,480 | $1,152 | 33.1% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 80 | 81 | $60,750 | $15,935 | 26.2% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 70 | 70 | $71,750 | $15,280 | 21.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 107 | 130 | $35,100 | $12,975 | 37.0% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 91 | 91 | $79,625 | $11,152 | 14.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 125 | 149 | $27,565 | $9,988 | 36.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 61 | 61 | $25,010 | $7,376 | 29.5% |
| 43239 | Biopsy of the esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 48 | 53 | $34,185 | $4,690 | 13.7% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2021 | 21 | 21 | $15,750 | $4,030 | 25.6% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 42 | 42 | $11,340 | $3,476 | 30.7% |
| 43235 | Diagnostic examination of esophagus, stomach, and/or upper small bowel using an endoscope | Facility | 2021 | 27 | 27 | $14,310 | $1,736 | 12.1% |
| 45378 | Diagnostic examination of the colon (large bowel) using an endoscope(colonoscopy); high risk | Facility | 2021 | 11 | 11 | $8,250 | $1,525 | 18.5% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 13 | 13 | $1,560 | $607.83 | 39.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 185 | 250 | $31,236 | $14,130 | 45.2% |
About Dr. Drew Ronnermann, MD
Dr. Drew Ronnermann, MD is a Gastroenterology healthcare provider based in Pottstown, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1235101999.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Drew Ronnermann, MD has received a total of $7,343 in payments from pharmaceutical and medical device companies, with $136.31 received in 2023. These payments were reported across 488 transactions from 43 companies. The most common payment nature is "Food and Beverage" ($7,273).
As a Medicare-enrolled provider, Ronnermann has provided services to 1,956 Medicare beneficiaries, totaling 2,162 services with total Medicare billing of $237,359. Data is available for 3 years (2020–2022), covering 36 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Pottstown, PA
- Active Since 02/06/2006
- Last Updated 07/13/2016
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1235101999
Products in Payments
- XIFAXAN (Drug) $1,064
- LINZESS (Drug) $415.87
- VIBERZI (Drug) $311.46
- STELARA (Biological) $302.35
- Entyvio (Biological) $226.14
- HUMIRA (Biological) $208.59
- ZEPOSIA (Drug) $208.39
- BREO (Drug) $186.18
- CREON (Drug) $184.14
- OCALIVA (Drug) $178.06
- REMICADE (Biological) $175.46
- ENTYVIO (Biological) $173.02
- Creon (Drug) $158.70
- DIFICID (Drug) $146.42
- Humira (Biological) $132.59
- INJECTAFER (Drug) $127.96
- TRULANCE (Drug) $121.44
- ZENPEP (Drug) $120.85
- Cimzia (Drug) $114.24
- Mulpleta (Drug) $108.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.